Overview

Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma

Status:
NOT_YET_RECRUITING

Trial end date:
2031-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this research is to test the safety of PD-1 inhibitor cemiplimab with or without LAG-3 inhibitor fianlimab, and see what effects (good and bad) of cemiplimab either alone or combined with fianlimab has on patients with oligometastatic clear cell renal cell carcinoma after completion of radiation therapy.

Phase:

PHASE2

Details

Lead Sponsor:

University of Oklahoma

Collaborator:

Regeneron Pharmaceuticals

Treatments:

cemiplimab